{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteer+Safety+Study&page=2",
    "query": {
      "condition": "Healthy Volunteer Safety Study",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteer+Safety+Study&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T21:53:25.886Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01597947",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "ACHN-975",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achaogen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 50,
      "start_date": "2012-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-21",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597947"
    },
    {
      "nct_id": "NCT03332732",
      "title": "VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "VNRX-5133",
          "type": "DRUG"
        },
        {
          "name": "VNRX-5022",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Venatorx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-10-24",
      "completion_date": "2017-12-20",
      "has_results": false,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332732"
    },
    {
      "nct_id": "NCT02374047",
      "title": "A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "CAT-2054",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CAT-2054-C",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catabasis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2015-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374047"
    },
    {
      "nct_id": "NCT01972152",
      "title": "Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "G-Pen(TM) 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Lilly Glucagon(TM) 1 mg",
          "type": "DRUG"
        },
        {
          "name": "G-Pen(TM) 0.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xeris Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-10",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972152"
    },
    {
      "nct_id": "NCT07344948",
      "title": "Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Schizophrenia Diagnosis"
      ],
      "interventions": [
        {
          "name": "NTX-253",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurosterix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 73,
      "start_date": "2025-10-03",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Los Alamitos, California",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07344948"
    },
    {
      "nct_id": "NCT05475821",
      "title": "Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-990",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-990",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-07-25",
      "completion_date": "2022-09-26",
      "has_results": false,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05475821"
    },
    {
      "nct_id": "NCT03978143",
      "title": "Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Treatment F",
          "type": "DRUG"
        },
        {
          "name": "Treatment G",
          "type": "DRUG"
        },
        {
          "name": "Treatment H",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-06-12",
      "completion_date": "2019-10-17",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978143"
    },
    {
      "nct_id": "NCT01742221",
      "title": "Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic Syndrome Due to Acute Radiation Syndrome"
      ],
      "interventions": [
        {
          "name": "HemaMax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Neumedicines Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2012-08",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742221"
    },
    {
      "nct_id": "NCT01756404",
      "title": "Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin (JNJ-28431754)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 80,
      "start_date": "2007-06-14",
      "completion_date": "2007-12-05",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756404"
    },
    {
      "nct_id": "NCT05213728",
      "title": "A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Norovirus Infections"
      ],
      "interventions": [
        {
          "name": "VXA-G1.1-NN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-24",
      "completion_date": "2022-02-24",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-06-26T21:53:25.886Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05213728"
    }
  ]
}